Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema

Human Gene Therapy

Volumn 20, Issue 6, 2009, Pages 598-610

  Watanabe, Masaki ^a   Boyer, Julie L ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; BEVACIZUMAB; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN A 165; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; MONOCLONAL ANTIBODY; VEGFA PROTEIN, HUMAN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRY WEIGHT; GENE TARGETING; GENE THERAPY; HISTOLOGY; HUMAN; LUNG EDEMA; LUNG LAVAGE; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; METABOLISM; ORGAN SIZE; PATHOLOGY; PERMEABILITY; PHOSPHORYLATION; TIME;

ADENOVIRIDAE; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; BRONCHOALVEOLAR LAVAGE FLUID; DRUG ADMINISTRATION ROUTES; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; HUMANS; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; PERMEABILITY; PHOSPHORYLATION; PULMONARY EDEMA; RNA, MESSENGER; TIME FACTORS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 68849084914     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.169     Document Type: Article

References (77)

1. Baca, M., and Wells, J.A. (1997). Anti-VEGF antibodies. Genentech, Inc. U.S. Patent 908469 [6884879].
2. Baca, M., Presta, L.G., O'Connor, S.J., and Wells, J.A. (1997). Antibody humanization using monovalent phage display. J. Biol. Chem. 272, 10678-10684.
3. Badros, A., Porter, N., and Zimrin, A. (2005). Bevacizumab therapy for POEMS syndrome. Blood 106, 1135.
4. Bates, D.O., Lodwick, D., and Williams, B. (1999). Vascular endothelial growth factor and microvascular permeability. Microcirculation 6, 83-96.
5. Becker, P.M., Alcasabas, A., Yu, A.Y., Semenza, G.L., and Bunton, T.E. (2000). Oxygen-independent upregulation of vascular endothelial growth factor and vascular barrier dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. Am. J. Respir. Cell Mol. Biol. 22, 272-279.
6. Bhandari, V., Choo-Wing, R., Chapoval, S.P., Lee, C.G., Tang, C., Kim, Y.K., Ma, B., Baluk, P., Lin, M.I., McDonald, D.M., Homer, R.J., Sessa, W.C., and Elias, J.A. (2006). Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc. Natl. Acad. Sci. U.S.A. 103, 11021-11026.
7. Bhandari, V., Choo-Wing, R., Lee, C.G., Yusuf, K., Nedrelow, J.H., Ambalavanan, N., Malkus, H., Homer, R.J., and Elias, J.A. (2008). Developmental regulation of NO-mediated VEGF-induced effects in the lung. Am. J. Respir. Cell Mol. Biol. 39, 420-430.
8. Breen, E.C. (2007). VEGF in biological control. J. Cell. Biochem. 102, 1358-1367.
9. Carpenter, T., Schomberg, S., Steudel, W., Ozimek, J., Colvin, K., Stenmark, K., and Ivy, D.D. (2003). Endothelin B receptor deficiency predisposes to pulmonary edema formation via increased lung vascular endothelial cell growth factor expression. Circ. Res. 93, 456-463.
10. Carpenter, T.C., Schomberg, S., and Stenmark, K.R. (2005). Endothelin-mediated increases in lung VEGF content promote vascular leak in young rats exposed to viral infection and hypoxia. Am. J. Physiol. Lung Cell Mol. Physiol. 289, L1075-L1082.
11. Choi, W.I., Quinn, D.A., Park, K.M., Moufarrej, R.K., Jafari, B., Syrkina, O., Bonventre, J.V., and Hales, C.A. (2003). Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am. J. Respir. Crit. Care Med. 167, 1627-1632.
12. De, B.P., Hackett, N.R., Crystal, R.G., and Boyer, J.L. (2008). Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. Mol. Ther. 16, 203-209.
13. Dvorak, H.F. (2006). Discovery of vascular permeability factor (VPF). Exp. Cell Res. 312, 522-526.
14. Dvorak, H.F., Brown, L.F., Detmar, M., and Dvorak, A.M. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039.
15. Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T., and Risau, W. (1998). Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol. 140, 947-959.
16. Ferrara, N. (2002). VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803.
17. Ferrara, N. (2004). Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 25, 581-611.
18. Ferrara, N., Gerber, H.P., and Lecouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
19. Ferrara, N., Hillan, K.J., Gerber, H.P., and Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400.
20. Ferrara, N., Hillan, K.J., and Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328-335.
21. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
22. Fox, W.D., Higgins, B., Maiese, K.M., Drobnjak, M., Cordon-Cardo, C., Scher, H.I., and Agus, D.B. (2002). Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 8, 3226-3231.
23. Fraser, R.S., Colman, N., Muller, N.L., and Pare, P.D. (1999). Pulmonary edema. In Fraser and Pare's Diagnosis of Diseases of the Chest. R.S. Fraser, N. Coleman, N.L. Muller, and P.D. Pare, eds. (W.B. Saunders, Philadelphia), pp. 1946-2017.
24. Fukumura, D., Gohongi, T., Kadambi, A., Izumi, Y., Ang, J., Yun, C.O., Buerk, D.G., Huang, P.L., and Jain, R.K. (2001). Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. U.S.A. 98, 2604-2609.
25. Gerber, H.P., and Ferrara, N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671-680.
26. Godzich, M., Hodnett, M., Frank, J.A., Su, G., Pespeni, M., Angel, A., Howard, M.B., Matthay, M.A., and Pittet, J.F. (2006). Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats. FASEB J. 20, 1519-1521.
27. Gorin, A.B., and Stewart, P.A. (1979). Differential permeability of endothelial and epithelial barriers to albumin flux. J. Appl. Physiol. 47, 1315-1324.
28. Gropper, M.A., and Wiener-Kronish, J. (2008). The epithelium in acute lung injury/acute respiratory distress syndrome. Curr. Opin. Crit. Care 14, 11-15.
29. Gurkan, O.U., O'Donnell, C., Brower, R., Ruckdeschel, E., and Becker, P.M. (2003). Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L710-L718.
30. Guyton, A.C., and Lindsey, A.W. (1959). Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ. Res. 7, 649-657.
31. Hackett, N.R., and Crystal, R.G. (2008). Adenovirus vectors for gene therapy. In Gene Therapy: Therapeutic Mechanisms and Strategies. Third Edition. D. Lasic and N.S. Templeton, eds. (Marcel Dekker, New York) pp. 39-68.
32. Hersh, J., Crystal, R.G., and Bewig, B. (1995). Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther. 2, 124-131.
33. Hippenstiel, S., Krull, M., Ikemann, A., Risau, W., Clauss, M., and Suttorp, N. (1998). VEGF induces hyperpermeability by a direct action on endothelial cells. Am. J. Physiol. 274, L678-L684.
34. Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J.P., Daly, T., Wiegand, S.J., Yancopoulos, G.D., and Rudge, J.S. (2002). VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 99, 11393-11398.
35. Hoyer, R.J., Leung, N., Witzig, T.E., and Lacy, M.Q. (2007). Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am. J. Hematol. 82, 409-413.
36. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
37. Kaner, R.J., and Crystal, R.G. (2001). Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol. Med. 7, 240-246.
38. Kaner, R.J., and Crystal, R.G. (2004). Pathogenesis of high altitude pulmonary edema: Does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak? High Alt. Med. Biol. 5, 399-409.
39. Kaner, R.J., Ladetto, J.V., Singh, R., Fukuda, N., Matthay, M.A., and Crystal, R.G. (2000). Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am. J. Respir. Cell Mol. Biol. 22, 657-664.
40. Karmpaliotis, D., Kosmidou, I., Ingenito, E.P., Hong, K., Malhotra, A., Sunday, M.E., and Haley, K.J. (2002). Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L585-L595.
41. Kim, K.J., Li, B., Houck, K., Winer, J., and Ferrara, N. (1992). The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53-64.
42. Kosmidou, I., Karmpaliotis, D., Kirtane, A.J., Barron, H.V., and Gibson, C.M. (2008). Vascular endothelial growth factors in pulmonary edema: An update. J. Thromb. Thrombolysis 25, 259-264.
43. Kowanetz, M., and Ferrara, N. (2006). Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin. Cancer Res. 12, 5018-5022.
44. Kunig, A.M., Balasubramaniam, V., Markham, N.E., Seedorf, G., Gien, J., and Abman, S.H. (2006). Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L1068-L1078.
45. Kuo, C.J., Farnebo, F., Yu, E.Y., Christofferson, R., Swearingen, R.A., Carter, R., Von Recum, H.A., Yuan, J., Kamihara, J., Flynn, E., D'Amato, R., Folkman, J., and Mulligan, R.C. (2001). Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. U.S.A. 98, 4605-4610.
46. Leaver, S.K., and Evans, T.W. (2007). Acute respiratory distress syndrome. BMJ 335, 389-394.
47. H2-mediated sensitization and inflammation in the lung. Nat. Med. 10, 1095-1103.
48. Mastrangeli, A., Danel, C., Rosenfeld, M.A., Stratford-Perricaudet, L., Perricaudet, M., Pavirani, A., Lecocq, J.P., and Crystal, R.G. (1993). Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J. Clin. Invest. 91, 225-234.
49. Matsumoto, T., and Claesson-Welsh, L. (2001). VEGF receptor signal transduction. Sci. STKE 2001, RE21.
50. Matthay, M.A., and Martin, T.A. (2005). Pulmonary edema and acute lung injury. In Murray and Nadel's Textbook of Respiratory Medicine. R. Mason, V. Broaddus, J. Murray, and J. Nadel, eds. (Elsevier Saunders, Philadelphia), pp. 1502-1543.
51. Matthay, M.A., Folkesson, H.G., and Clerici, C. (2002). Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol. Rev. 82, 569-600.
52. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcom, P.K., Fehrenbacher, L., Dickler, M., Overmoyer, B.A., Reimann, J.D., Sing, A.P., Langmuir, V., and Rugo, H.S. (2005). Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792-799.
53. Mittereder, N., March, K.L., and Trapnell, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
54. Montaner, J.S., Tsang, J., Evans, K.G., Mullen, J.B., Burns, A.R., Walker, D.C., Wiggs, B., and Hogg, J.C. (1986). Alveolar epithelial damage: A critical difference between high pressure and oleic acid-induced low pressure pulmonary edema. J. Clin. Invest. 77, 1786-1796.
55. Muhlhauser, J., Merrill, M.J., Pili, R., Maeda, H., Bacic, M., Bewig, B., Passaniti, A., Edwards, N.A., Crystal, R.G., and Capogrossi, M.C. (1995). VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ. Res. 77, 1077-1086.
56. Mura, M., Dos Santos, C.C., Stewart, D., and Liu, M. (2004). Vascular endothelial growth factor and related molecules in acute lung injury. J. Appl. Physiol. 97, 1605-1617.
57. Olsson, A.K., Dimberg, A., Kreuger, J., and Claesson-Welsh, L. (2006). VEGF receptor signalling: In control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371.
58. Pichelmayer, O., Zielinski, C., and Raderer, M. (2005). Response of a nonmalignant pleural effusion to bevacizumab. N. Engl. J. Med. 353, 740-741.
59. Plikaytis, B.D., Turner, S.H., Gheesling, L.L., and Carlone, G.M. (1991). Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 29, 1439-1446.
60. Presta, L.G., Chen, H., O'Connor, S.J., Chisholm, V., Meng, Y.G., Krummen, L., Winkler, M., and Ferrara, N. (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599.
61. Proescholdt, M.A., Heiss, J.D., Walbridge, S., Muhlhauser, J., Capogrossi, M.C., Oldfield, E.H., and Merrill, M.J. (1999). Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J. Neuropathol. Exp. Neurol. 58, 613-627.
62. Roberts, W.G., and Palade, G.E. (1995). Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108, 2369-2379.
63. 1- antitrypsin gene to the lung epithelium in vivo. Science 252, 431-434.
64. Rosenfeld, M.A., Yoshimura, K., Trapnell, B.C., Yoneyama, K., Rosenthal, E.R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L.E., Stratford- Perricaudet, L., Perricaudet, M., Guggino, W.B., Pavirani, A., Lecocq, J.-P., and Crystal, R.G. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
65. Rosenstein, J.M., and Krum, J.M. (2004). New roles for VEGF in nervous tissue: Beyond blood vessels. Exp. Neurol. 187, 246-253.
66. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R., and Johnson, D.H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550.
67. Schoch, H.J., Fischer, S., and Marti, H.H. (2002). Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 125, 2549-2557.
68. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., and Dvorak, H.F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
69. Staub, N.C. (1974). Pulmonary edema. Physiol. Rev. 54, 678-811.
70. Sweeney, C.J., Miller, K.D., Sissons, S.E., Nozaki, S., Heilman, D.K., Shen, J., and Sledge, G.W., Jr. (2001). The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61, 3369-3372.
71. Thickett, D.R., Armstrong, L., Christie, S.J., and Millar, A.B. (2001). Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 164, 1601-1605.
72. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J.C., and Abraham, J.A. (1991). The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954.
73. Turner, C.R., Zuczek, S., Knudsen, D.J., and Wheeldon, E.B. (1990). Microwave fixation of the lung. Stain Technol. 65, 95-101.
74. Voelkel, N.F., Vandivier, R.W., and Tuder, R.M. (2006). Vascular endothelial growth factor in the lung. Am. J. Physiol. Lung Cell Mol. Physiol. 290, L209-L221.
75. Watanabe, M., Boyer, J.L., Hackett, N.R., Qiu, J., and Crystal, R.G. (2008). Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice. Hum. Gene Ther. 19, 300-310.
76. Wheeler, A.P., and Bernard, G.R. (2007). Acute lung injury and the acute respiratory distress syndrome: A clinical review. Lancet 369, 1553-1564.
77. Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X., and Rosenberg, S.A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434.